Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.42 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6378958 | 0.97 | SLC18A3 (0.45) | SLC18A3PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL2004934 | 0.97 | SLC18A3 (0.45) | SLC18A3PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL736823 | 0.97 | SLC18A3 (0.45) | SLC18A3PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL735809 | 0.94 | L3MBTL3 (0.38) | SLC18A3PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL2009840 | 0.93 | L3MBTL3 (0.39) | SLC18A3PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL2003194 | 0.91 | L3MBTL3 (0.42) | SLC18A3L3MBTL3L3MBTL1HTR6MEN1 | |
| SCHEMBL2011528 | 0.91 | SLC18A3 (0.41) | SLC18A3PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL2011143 | 0.91 | SLC18A3 (0.41) | SLC18A3PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL2003309 | 0.89 | L3MBTL3 (0.41) | SLC18A3PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL2006298 | 0.89 | L3MBTL3 (0.41) | SLC18A3PHGDHMGLLL3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3077387-B1 | BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-20 | — | — | EP | claimed |
| US-9562035-B2 | Benzamide derivative useful as FASN inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-07 | — | — | US | claimed |
| US-9499558-B2 | Compounds and methods for treating HIV | PURDUE RESEARCH FOUNDATION (US) | 2016-11-22 | — | — | US | claimed |
| EP-3077387-A1 | BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | Janssen Pharmaceutica, N.V. (BE) | 2016-10-12 | — | — | EP | claimed |
| US-9346820-B2 | HIV-1 protease inhibitors having gem-di-fluoro bicyclic P2-ligands | PURDUE RESEARCH FOUNDATION (US) | 2016-05-24 | — | — | US | claimed |
| US-20160009688-A1 | BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-14 | — | — | US | claimed |
| US-20150225414-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-13 | — | — | US | claimed |
| WO-2015084606-A1 | BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-11 | — | — | WO | claimed |
| US-9024038-B2 | Compunds and methods for treating HIV | PURDUE RESEARCH FOUNDATION (US) | 2015-05-05 | — | — | US | claimed |
| CN-102153544-B | Preparation method and application of novel tyrosine kinase inhibitors | SHANGHAI SUN SAIL PHARMACEUTICAL SCIENCE & TECHNOLOGY CO LTD | 2015-04-29 | — | — | CN | claimed |
| US-20150072958-A1 | HIV-1 PROTEASE INHIBITORS HAVING GEM-DI-FLUORO BICYCLIC P2-LIGANDS | PURDUE RESEARCH FOUNDATION | 2015-03-12 | — | — | US | claimed |
| WO-2015028989-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ANTIMALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-03-05 | — | — | WO | claimed |
| US-20130289067-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | PURDUE RESEARCH FOUNDATION | 2013-10-31 | — | — | US | claimed |
| CN-103347385-A | Diazeniumdiolate heterocyclic derivatives | MERCK SHARP & DOHME | 2013-10-09 | — | — | CN | claimed |
| CN-102153544-A | Preparation method and application of novel tyrosine kinase inhibitors | SHANGHAI SUN SAIL PHARMACEUTICAL SCIENCE & TECHNOLOGY CO LTD | 2011-08-17 | — | — | CN | claimed |
| EP-1667647-A4 | MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-10-22 | — | — | EP | claimed |
| CN-1812981-A | Heteroaryloxy nitrogenous saturated heterocyclic derivative | BANYU PHARMA CO LTD (JP) | 2006-08-02 | — | — | CN | claimed |
| EP-1667647-A2 | MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-06-14 | — | — | EP | claimed |
| US-20050107361-A1 | Monocyclic and bicyclic lactams as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMANY | 2005-05-19 | — | — | US | claimed |
| WO-2005032468-A2 | MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225414-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | SERPINB1, HPN, DNPEP | SLC18A3 3090/4885PHGDH 898/4885MGLL 442/4885 |
| US-20130289067-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | SERPINB1, HPN, DNPEP | SLC18A3 3090/4885PHGDH 898/4885MGLL 442/4885 |
| US-20150072958-A1 | HIV-1 PROTEASE INHIBITORS HAVING GEM-DI-FLUORO BICYCLIC P2-LIGANDS | PREP, DPEP1, BACE1 | SLC18A3 721/4885PHGDH 1003/4885MGLL 257/4885 |
| US-20050107361-A1 | Monocyclic and bicyclic lactams as factor Xa inhibitors | F2, F12, SPINT2 | SLC18A3 3936/4885PHGDH 4080/4885MGLL 1121/4885 |
| US-20160009688-A1 | BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, FABP1, BCL3 | SLC18A3 4771/4885PHGDH 1228/4885MGLL 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.